SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-018789
Filing Date
2024-03-01
Accepted
2024-03-01 09:21:14
Documents
32
Period of Report
2024-02-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0200995-8k_allarity.htm   iXBRL 8-K 28926
2 AMENDMENT SENIOR CONVERTIBLE NOTES ea0200995ex10-1_allarity.htm EX-10.1 12255
3 COMPANY PRESENTATION SLIDES ea0200995ex99-1_allarity.htm EX-99.1 22789
4 GRAPHIC ex99-1_001.jpg GRAPHIC 96807
5 GRAPHIC ex99-1_002.jpg GRAPHIC 716715
6 GRAPHIC ex99-1_003.jpg GRAPHIC 71893
7 GRAPHIC ex99-1_004.jpg GRAPHIC 262939
8 GRAPHIC ex99-1_005.jpg GRAPHIC 264090
9 GRAPHIC ex99-1_006.jpg GRAPHIC 224569
10 GRAPHIC ex99-1_007.jpg GRAPHIC 266630
11 GRAPHIC ex99-1_008.jpg GRAPHIC 376682
12 GRAPHIC ex99-1_009.jpg GRAPHIC 230841
13 GRAPHIC ex99-1_010.jpg GRAPHIC 52681
14 GRAPHIC ex99-1_011.jpg GRAPHIC 226272
15 GRAPHIC ex99-1_012.jpg GRAPHIC 254754
16 GRAPHIC ex99-1_013.jpg GRAPHIC 126300
17 GRAPHIC ex99-1_014.jpg GRAPHIC 332929
18 GRAPHIC ex99-1_015.jpg GRAPHIC 186685
19 GRAPHIC ex99-1_016.jpg GRAPHIC 103299
  Complete submission text file 0001213900-24-018789.txt   5474642

Data Files

Seq Description Document Type Size
20 XBRL SCHEMA FILE allr-20240227.xsd EX-101.SCH 3015
21 XBRL LABEL FILE allr-20240227_lab.xml EX-101.LAB 34240
22 XBRL PRESENTATION FILE allr-20240227_pre.xml EX-101.PRE 22359
33 EXTRACTED XBRL INSTANCE DOCUMENT ea0200995-8k_allarity_htm.xml XML 3726
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 24707278
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)